BLC website featuresBCAN announcementBLC 3:4, article 2, figure 2Investigating the predictive impact of the proliferation biomarker Ki-67Expression status of hypoxia related markers in bladder cancer tissue.Generating the muscle invasive bladder cancer interactome.The synergistic relationship between immunotherapy and radiation.

Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the funding analyzer.

We are pleased to announce that, as of 2018, Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities at: http://tiny.cc/BLC_PR

This study undertakes a quantitative assessment of heterogeneity in bladder tumor MRI diffusivity, showing the ADC heterogeneity in the bladder tumor of a responder (upper) vs. a non-responder (lower). From: HT Nguyen et al., Bladder Cancer, vol. 3, no. 4, pp. 237244, 2017

 

Investigating the impact of the proliferation biomarker Ki-67 in initial stage pTa urothelial carcinoma of the bladder. Examples of low (<10%, A) and strong (≥50%, B) staining of Ki-67 under 5 fold and 40 fold magnification. From: Breyer, et al., Bladder Cancer, vol. 3, no. 3, pp. 173180, 2017

Expression status of hypoxia related markers in bladder cancer tissue.  Immunohistochemistry staining of HIF1a, CA-IX, GLUT-1 and Ki-67 in paraffin-embedded TMA sections of bladder cancer tissues. From: Boström et al., Bladder Cancer, vol. 2, no. 1, pp. 101109, 2016

Generating the muscle invasive bladder cancer interactome. From: Bhat et al., Bladder Cancer, vol. 2, no. 1, pp. 6576, 2016

The synergistic relationship between immunotherapy and radiation. From Buchwald and Efstathiou. Bladder Cancer, vol. 1, no. 1, pp. 1527, 2016

Welcome to Bladder Cancer

Paper Alert

Between 15 and 20% of patients with newly diagnosed urothelial cancer (UC) of the bladder will have high grade (HG) non-muscle invasive (NMI) disease including...

In 2014, I was on the Board of Directors of the Society of Urologic Oncology (SUO) when Merck announced having shortages of Tice strain Bacillus...

The standard initial treatment for urothelial cancer and other tumors of the bladder is a complete transurethral resection (TURBT). This is, of course, also a...

Paper Alert

Between 15 and 20% of patients with newly diagnosed urothelial cancer (UC) of the bladder will have high grade (HG) non-muscle invasive (NMI) disease including...

In 2014, I was on the Board of Directors of the Society of Urologic Oncology (SUO) when Merck announced having shortages of Tice strain Bacillus...

No front page content has been created yet.